L’IMI JU (Innovative Medicines Initiative Joint Undertaking) lo scorso 9 luglio ha lanciato la quinta Call for proposals per finanziamenti europei a progetti di ricerca nell’ambito di IMI 2 con i seguenti topic:
Topic 1 (IMI2-2015-05-01): Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and Health Technology Assessment bodies.- Topic 2 (IMI2-2015-05-02): Diabetic Kidney Disease Biomarkers (DKD-BM).
- Topic 3 (IMI2-2015-05-03): Inflammation and AD: modulating microglia function – focussing on TREM2 and CD33.
- Topic 4 (IMI2-2015-05-04): Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from predementia to dementia).
- Topic 5 (IMI2-2015-05-05): Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease: Phased expansion study.
- Topic 6 (IMI2-2015-05-06): From ApoE biology to validated Alzheimer’s disease targets.
Le proposte sono soggette ad una procedura di sottomissione a due stadi: la deadline per la presentazione delle proposte allo stage 1 è fissata al 13/10/2015. Nell’autunno del 2015 è previsto il lancio di nuove calls, per le quali sono allo studio i seguenti topic:
- Joint influenza vaccine effectiveness surveillance;
- Development of quantitative system toxicology (QST) approaches to improve the understanding of the safety of new medicines;
- Establishing impact of RSV (respiratory syncytial virus) infection, resultant disease and public health approach to reducing the consequences;
- Coordination and Support Action (CSA) for the Big Data for Better Outcomes programme;
- Real world outcomes across the AD (Alzheimer’s disease) spectrum (ROADS) to better care;
- Development of an outcomes-focused platform to empower policy makers and clinicians to optimize care for patients with haematologic malignancies.
Le informazioni finali sulle future calls IMI saranno comunicate dopo l’approvazione da parte dell’IMI Governing Board.
Fonte: imi.europa.eu
©RIPRODUZIONE RISERVATA
©RIPRODUZIONE RISERVATA
